Quantum Psychiatric Field Hypothesis (QPFH)

The Quantum Psychiatric Field Hypothesis (QPFH) posits that decoherence in a quantized scalar field, P(x,t), representing microtubule dynamics, biophoton emissions, and neural oscillations, contributes to neural dysconnectivity in psychiatric disorders [1]. Extending the Conscious Quantum Field Hypothesis (CQFH) [1], QPFH proposes that disruptions in quantum processes, including microtubule coherence, biophoton signaling, and theta/gamma oscillations, influence transdiagnostic symptoms such as sensory, cognitive, and emotional impairments, and subconscious processing deficits [36, 64, 69]. High comorbidity rates, including OCD with anxiety (50–60%) [36, 89], depression with anxiety (40–50%) [36, 64], and autism with ADHD (10–20%) [51], reflect shared dysconnectivity, evidenced by symptoms like emotional dysregulation, sensory overload, and cognitive biases [36, 64, 89, 35, 98]. Emerging theoretical findings from tryptophan superradiance [6], biophoton dysregulation [7], EEG-cytokine interactions [81, 9], and blood-brain barrier dysfunction [10, 11] suggest potential quantum contributions to QPFH’s model. Eight proposed experiments (2026–2033) using EEG, THz spectroscopy, and biophoton analysis aim to test synchrony deficits [33, 32, 111]. Environmental stressors, neuroinflammation, genetic variants (e.g., CACNA1C, SCN2A), and epigenetic modifications modulate decoherence [10, 16, 30, 96]. Medications influence neurotransmitter pathways, with side effects potentially affecting microtubule dynamics, warranting further investigation [17, 18, 6, 41]. Targeted therapies, including transcranial photobiomodulation (tPBM) and quantum-inspired neurofeedback, enhance neural synchrony [82, 109, 93], while proposed interventions like transcranial alternating current stimulation (tACS) for OCD and schizophrenia, and nanotherapeutics for schizophrenia and BPD offer additional avenues for exploration [19, 20, 76, 72]. Diagnostic markers, such as olfactory deficits, pituitary endorphin dysregulation, mirror neuron impairments, and gut-brain axis alterations, guide transdiagnostic approaches [36, 64, 81, 35, 2]. Quantum coherence in glial cells and epigenetic modulation of quantum processes provide further research directions [61, 97]. Despite its intent, QPFH remains speculative, with challenges in measuring quantum coherence [1, 50].